GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cosciens Biopharma Inc (NAS:CSCI) » Definitions » 1-Year Sharpe Ratio

CSCI (Cosciens Biopharma) 1-Year Sharpe Ratio : -0.84 (As of Jun. 17, 2025)


View and export this data going back to 1992. Start your Free Trial

What is Cosciens Biopharma 1-Year Sharpe Ratio?

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2025-06-17), Cosciens Biopharma's 1-Year Sharpe Ratio is -0.84.


Competitive Comparison of Cosciens Biopharma's 1-Year Sharpe Ratio

For the Biotechnology subindustry, Cosciens Biopharma's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosciens Biopharma's 1-Year Sharpe Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's 1-Year Sharpe Ratio falls into.


;
;

Cosciens Biopharma 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.


Cosciens Biopharma  (NAS:CSCI) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Cosciens Biopharma 1-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Cosciens Biopharma's 1-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosciens Biopharma Business Description

Traded in Other Exchanges
Address
c/o Norton Rose Fulbright Canada LLP, 222 Bay Street, Suite 3000, P.O. Box 53, Toronto, ON, CAN, M5K 1E7
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.